Quick Answer
Valion Bio, Inc. reported R&D Expense of $3.13 million for fiscal year 2025.
Valion Bio, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $3.13M | +138.5% |
| 2024 | $1.31M | -20.7% |
| 2023 | $1.66M | -4.3% |
| 2022 | $1.73M | +97.0% |
| 2021 | $878.0K | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $858.0K | +103.3% | +31.0% |
| June 30, 2025 | $655.0K | +116.9% | +95.5% |
| March 31, 2025 | $335.0K | +30.9% | -20.6% |
| September 30, 2024 | $422.0K | +25.2% | +39.7% |
| June 30, 2024 | $302.0K | -35.5% | +18.0% |
| March 31, 2024 | $256.0K | -47.8% | -24.0% |
| September 30, 2023 | $337.0K | -15.5% | -28.0% |
| June 30, 2023 | $468.0K | -5.8% | -4.5% |
- Valion Bio, Inc. showed an increase of +138.5% in R&D Expense compared to the prior fiscal year.
- Over the 2021–2025 period, Valion Bio, Inc.’s r&d expense has grown by 256.6% (from $878.0 thousand to $3.13 million).
- The most recent figure is from Valion Bio, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: